Hypertension control: Results from the Diabetes Care Program of Nova Scotia registry and impact of changing clinical practice guidelines

Cardiovascular Diabetology

Volumn 4, Issue , 2005, Pages

  Russell, Cory ^a   Dunbar, Peggy ^b   Salisbury, Sonia ^b   Sketris, Ingrid ^a   Kephart, George ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Cancer Care Nova Scotia   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE CONTROL; DRUG USE; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRACTICE GUIDELINE; RANDOMIZATION; REGISTER; RISK FACTOR; SELF REPORT; VASCULAR DISEASE; COHORT ANALYSIS; MIDDLE AGED; STATISTICAL MODEL;

ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; NOVA SCOTIA; PRACTICE GUIDELINES AS TOPIC; REGISTRIES;

EID: 26844455747     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-4-11     Document Type: Article

References (28)

1. Wolf HK, Andreou P, Bata IR, Comeau DG, Gregor RD, Kephart G, et al.: Trends in the prevalence and treatment of hypertension in Halifax County from 1985 to 1995. CMAJ 1999, 161:699-704.
2. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al.: 1998 clinical practice guidelines for the management of diabetes in Canada. In CMAJ Volume 159. Canadian Diabetes Association; 1998:S1-S29.
3. Johansen OE, Birkeland KI: Preventing Macrovascular Disease in patient with Type 2 Diabetes Mellitus. Am J Cardiovasc Drugs 2003, 3(4):283-297.
4. The UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998, 317:703-13.
5. Haffner SM: The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998, 19(5):583-92.
6. Kannel WB, Mcgee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59(1):8-13.
7. Joffres MR, Hamet P, MacLean DR, L'italien GJ, Fodor G: Distribution of blood pressure and hypertension in Canada and the United States. AJH 2001, 14:1099-1105.
8. Dunbar, Peggy MEd, PDT, Coordinator for the Diabetes Care Program of Nova Scotia: Personal communication 2003.
9. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
10. Mogensen CE: Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ 1998, 317:693-4.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289(19):2560-2572.
12. Adler AI, Stratton IM, Neil HA, Yudkin JS, Mathhew DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:413-419.
13. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
14. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16(2):434-444.
15. Carruthers SG, Hypertension in Gray J: Therapeutic Choices. Canadian Pharmacists Association 2000:180-190.
16. American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 2004:S15-35.
17. Canadian Diabetes Association Clinical Practice Guidelines Expert-Committee: Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003, 27(suppl 2):S1-S152.
18. Expert Committee of the Canadian Diabetes Advisory Board: Clinical practice guidelines for treatment of diabetes mellitus. CMAJ 1992, 147(5):697-712.
19. Feldman RD, et al.: Canadian Recommendations for the Management of Hypertension. CMAJ 1999, 161:S1-17.
20. Canadian Hypertension Education Program, [http://www.hypertension.ca/Documentation/Recommendations2003.pdf]
21. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
22. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C: Screening early renal failure: Cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999, 55(5):1878-84.
23. World Health Organization Collaborating Centre for Drug Statistics Methodology: ATC Index with DDDs, 2002. Oslo, Norway: World Health Organization; 2002.
24. Toth EL, Majumdar SR, Guirguis LM, Lewanczuk RZ, Lee TK, Johnson JA: Compliance with Clinical Practice Guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement. Pharmacotherapy 2003, 23:659-65.
25. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB: Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with Type 2 diabetes. Am J Med 2002, 112:603-9.
26. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
27. Kwon A, Bungay KM, Pei Y, Rogers WH, Wilson IB, Zhou Q, Adler DA: Antidepressant use: concordance between self-report and claims records. Med Care 2003, 41(3):368-74.
28. Saunders K, Simon G, Bush T, Grothaus L: Assessing the feasibility of using computerized pharmacy refill data to monitor anti-depressant treatment on a population basis: a comparison of automated and self-report data. J Clin Epidemiol 1998, 51(10):883-90.